Neodyne Biosciences' Embrace Patch: A Breakthrough for Lipohypertrophy in Diabetes Care

Neodyne Biosciences' Embrace Active Site Care Patch: A Game Changer in Diabetes Treatment

In a groundbreaking achievement for diabetes care, Neodyne Biosciences announced that its embrace® Active Site Care compression patch is the first medical device empirically validated to significantly alleviate lipohypertrophy (LH) in patients with insulin-dependent diabetes. This significant advancement was recently presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, where researchers revealed promising results from a 16-week clinical trial involving individuals with longstanding LH lesions.

Lipohypertrophy is a common complication affecting approximately 64% of insulin users, caused by repeated insulin injections leading to a build-up of fat and fibrous scar tissue at the injection sites. This condition not only causes discomfort but also interferes with insulin absorption, leading to greater fluctuations in blood glucose levels, hypoglycemia, and elevated A1C readings. Previously, there were limited treatments available, forcing patients to either rotate injection sites or avoid areas of trouble entirely.

The embrace patch was developed to address this under-discussed yet critical issue in diabetes management. In this trial, patients applied the patch to target lesions every ten days over the course of 16 weeks. Investigators meticulously assessed lesion volume and tissue quality through ultrasound and biopsy techniques. The findings confirmed that the embrace patch led to a significant reduction in LH lesion volume—averaging a 20% decrease when compared to untreated lesions—as noted by ultrasound imaging.

Moreover, the therapy demonstrated an impressive histological improvement, with treated LH lesions displaying an average reduction in adipocyte lipid content by a striking factor of 6.97. Analysis of tissue samples indicated that the fibrosis characteristic of LH was significantly reduced, pointing to the embrace patch's ability to rehabilitate compromised tissue structures effectively.

The clinical trial's outcomes also conveyed high patient satisfaction; participants reported that the embrace patch was user-friendly and comfortable—factors that could highly influence the quality of their diabetes treatment experience. In fact, approximately 63% of the participants regained the use of previously exhausted injection sites, indicating a remarkable enhancement in their diabetes management capabilities.

Dr. Hans DeVries, the lead scientist at Profil Institute for Metabolic Research, emphasized the trial's implications, stating, "The findings from this trial reveal that the embrace patch significantly improves long-standing LH lesions — a breakthrough that could provide effective treatment for a widespread complication that many insulin users endure."

Kelley Lipman, President and CEO of Neodyne Biosciences, noted this development marks a pivotal moment in diabetes care. "Clinicians now have access to an evidence-based solution specifically designed to tackle LH—a recognized barrier to effective insulin therapy. Managing lipohypertrophy is essential not just for site health but also for improving insulin availability and refining glycemic control."

The embrace Active Site Care patch operates using a state-of-the-art mechanism to offload tension on the skin, which aids in mitigating the underlying issues of LH. As a promising new addition to diabetes treatment options, the embrace technology may facilitate a shift towards improved quality of life for millions of insulin users facing similar challenges.

Looking ahead, embrace will be showcased further at the ADA Scientific Sessions with the intent to inform more healthcare professionals about its workings and benefits. The poster presentation, titled “A Weekly Tension Offloading Patch for Lipohypertrophy,” will be on display until June 23 in the McCormick Place Convention Center.

In summary, Neodyne Biosciences not only offers hope but potentially transformative outcomes for individuals struggling with lipohypertrophy. The embrace Active Site Care patch brings a new sense of empowerment and control back to the realm of diabetes management—highlighting the importance of innovation in healthcare solutions for chronic conditions.